Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges

Executive Summary

Risk mitigation in the oncology setting is unique, largely because of the different benefit/risk ratio, but also because the therapeutic area has "a de facto restricted distribution system," as FDA Office of Oncology Drug Products Director Richard Pazdur put it.
Advertisement

Related Content

Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate
To REMS Or Not To REMS? Erivedge Shows Division At FDA Over Oncology Risk Management
FDA’s Decision To Back Off Korlym REMS Shows Context Is King
Eliminating MedGuide-Only REMS Merits PDUFA-Style Deadlines, PhRMA Says
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
Egrifta Approval: FDA Balanced Modest Efficacy, Off-Label Use Potential With Unmet Medical Need
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements
Surrogate Endpoints Don't Convince ODAC: Panel Votes No On Two Centocor/Ortho Biotech Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS053492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel